Leveraging Lessons Learned During the Pandemic to Advance the Future of LFI Manufacturing

Tuesday, September 28, 12:30 - 12:50 p.m.
Exhibit Hall, Theater 2
Supported by Web Industries Medical

Overview

By exposing the general public to the convenience of rapid Lateral Flow Immunoassay (LFI) tests, the pandemic opened new market segments for those devices. At the same time, massive industry investment in response to the pandemic significantly increased innovation and capacity, possibly advancing the diagnostics market by a decade. As healthcare emerges from the shadow of COVID-19, what do medical device companies and contract development organizations need to know to succeed?

During this presentation, we will review the lessons learned as we successfully ramped production to millions of LFI devices per week. Leveraging design-for-automated-manufacturing knowledge, robust quality assurance, and resilient supply chain management, our experiences can help the industry speed the development and rollout of future LFI tests to enable better health outcomes.

Outcomes

After attending this session, participants will be able to:

  • Balance the relationship between quality requirements, speed-to-market, and manufacturing best practices.
  • Recognize how critical-to-quality requirements can become a risk if not properly managed.
  • Understand the need to optimize test designs to leverage manufacturing technologies.

Presenters

Miranda Conary
SARS-CoV-2 Program Manager
Web Industries

Claudio Hanna
Medical Market Director
Web Industries